Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology
The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Histone deacetylases (HDACs) are expressed at increased levels in cells of various malignancies, and the use of HDAC inhibitors has improved outcomes in patients with haematological malignancies (T-cell lymphomas and multiple myeloma). However, they are not as effective in solid tumours. Five agents are currently approved under various jurisdictions, namely belinostat, chidamide, panobinostat, romidepsin and vorinostat. These agents are associated with a range of class-related and agent-specific serious and/or severe adverse effects, notably myelosuppression, diarrhoea and various cardiac effects. Among the cardiac effects are ST-T segment abnormalities and QTc interval prolongation of the electrocardiogram, isolated cases of atrial fibrillation and, in rare instances, ventricular tachyarrhythmias. In order to improve the safety profile of this class of drugs as well as their efficacy in indications already approved and to further widen their indications, a large number of newer HDAC inhibitors with varying degrees of HDAC isoform selectivity have been synthesised and are currently under clinical development. Preliminary evidence from early studies suggests that they may be effective in non-haematological cancers as well when used in combination with other therapeutic modalities, but that they too appear to be associated with the above class-related adverse effects. As the database accumulates, the safety, efficacy and risk/benefit of the newer agents and their indications wi…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“KDAC inhibitors often exhibit sub-optimal efficacy in the clinic (especially when administered to patients with solid tumors) as well as side effects such as blood thinning, cardiac abnormalities, and nausea/vomiting [28].”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [28]
In the citing paper
“There is increasing evidence that KDAC inhibitors work best in combination with other therapies [28–30]”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [28]
In the citing paper
“HDAC3 was found to be required for genome maintenance and DNA replication in hematopoietic cells (27, 28); therefore, HDAC3 inhibition is suspected to be responsible for bone marrow toxicity seen with nonselective HDAC inhibitors (29).”
From TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11 -Mutant Tumors to Anti–PD-1 Immunotherapy (2025) · cites this paper as [29]
Citations
Cites
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
Suraweera, A., O’Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 669
Histone deacetylases, transcriptional control, and cancer
Cress, W. D., & Seto, E. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200007)184:1<1::aid-jcp1>3.0.co;2-7 · Cited by 621
Molecular and Therapeutic Potential and Toxicity of Valproic Acid
Chateauvieux, S., Morceau, F., Dicato, M., & Diederich, M. (2010) · Journal of Biomedicine and Biotechnology · doi:10.1155/2010/479364 · Cited by 512
Targeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need To Succeed
Gryder, B. E., Sodji, Q. H., & Oyelere, A. K. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.3 · Cited by 404
Clinical Toxicities of Histone Deacetylase Inhibitors
Subramanian, S., Bates, S. E., Wright, J. J., Espinoza-Delgado, I., & Piekarz, R. L. (2010) · Pharmaceuticals · doi:10.3390/ph3092751 · Cited by 386
Shi, Y., Dong, M., Hong, X., Zhang, W., Feng, J., Zhu, J., Yu, L., Ke, X., Huang, H., Shen, Z., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv237 · Cited by 385
Histone acetylation and disease
Timmermann, S., Lehrmann, H., Polesskaya, A., & Harel-Bellan, A. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000896 · Cited by 341
Cited by
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Ho, T. C. S., Chan, A. H. Y., & Ganesan, A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00830 · Cited by 795
Recent developments of HDAC inhibitors: Emerging indications and novel molecules
Bondarev, A. D., Attwood, M. M., Jonsson, J., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14889 · Cited by 416
“reason for this could be the pharmacokinetic differences between the drugs.(177) The orally available vorinostat has a short half-life (2 hours) and its time to reach peak plasma concentration is 5.”
BackgroundEpigenetic modulation and understanding of HDAC inhibitors in cancer therapy
Ramaiah, M. J., Tangutur, A. D., & Manyam, R. R. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119504 · Cited by 345
Epigenetics-targeted drugs: current paradigms and future challenges
Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02039-0 · Cited by 339
Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang, T., Wang, F., Elhassan, R. M., Cheng, Y., Tang, X., Chen, W., Fang, H., & Hou, X. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.007 · Cited by 222
Metadata
- Authors
- Shah, R. R.
- Corresponding author
- Shah, Rashmi R.
- ORCID
- Shah, Rashmi R.
- Venue
- Drug Safety
- Published
- 2019-01-16
- Volume
- 42
- Issue
- 2
- Pages
- 235-245
- ISSN
- 0114-5916 (ISSN-L)
- 1179-1942
- OpenAlex
- W2910383661
- Cited by
- 197
- References
- 69
- Citations by year
- 2026: 24 · 2025: 46 · 2024: 26 · 2023: 25 · 2022: 25 · 2021: 24 · 2020: 19 · 2019: 7
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Drug Safety (publishedVersion, public-domain)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- histone deacetylase inhibitors, tolerability, adverse drug reactions, myelosuppression, diarrhea, cardiotoxicity, QTc prolongation, atrial fibrillation, ventricular tachyarrhythmia, belinostat, chidamide, panobinostat, romidepsin, vorinostat, HDAC isoform selectivity, solid tumors, hematologic malignancies, T-cell lymphoma, multiple myeloma, combination therapy
- MeSH terms
- Animals, Antineoplastic Agents, Gastrointestinal Diseases, Histone Deacetylases, Humans, Hydroxamic Acids, Neoplasms, Sulfonamides, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology. https://app.cochat.ai/papers/10.1007/s40264-018-0773-9
- The paper
- Shah, R. R. (2019). Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology. Drug Safety. https://doi.org/10.1007/s40264-018-0773-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.